NASDAQ:CERS

Cerus Competitors

$6.13
+0.06 (+0.99 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.93
Now: $6.13
$6.14
50-Day Range
$5.68
MA: $6.28
$7.49
52-Week Range
$4.87
Now: $6.13
$8.87
Volume1.72 million shs
Average Volume2.26 million shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37

Competitors

Cerus (NASDAQ:CERS) Vs. ALGN, WST, COO, XRAY, HAE, and STAA

Should you be buying CERS stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Cerus, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and STAAR Surgical (STAA).

Cerus (NASDAQ:CERS) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.2% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and Align Technology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
Align Technology13902.62

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. Align Technology has a consensus target price of $501.3333, suggesting a potential downside of 15.40%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than Align Technology.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Profitability

This table compares Cerus and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
Align Technology76.00%68.99%46.64%

Earnings & Valuation

This table compares Cerus and Align Technology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
Align Technology$2.41 billion19.48$442.78 million$4.96119.47

Align Technology has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Cerus on 11 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and West Pharmaceutical Services, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
West Pharmaceutical Services01202.67

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential upside of 4.55%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than West Pharmaceutical Services.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Cerus and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
West Pharmaceutical Services14.69%19.01%12.78%

Earnings & Valuation

This table compares Cerus and West Pharmaceutical Services' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
West Pharmaceutical Services$1.84 billion11.90$241.70 million$3.2491.52

West Pharmaceutical Services has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Summary

West Pharmaceutical Services beats Cerus on 8 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Cerus and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
The Cooper Companies9.81%12.79%7.20%

Earnings & Valuation

This table compares Cerus and The Cooper Companies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05

The Cooper Companies has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.4% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and The Cooper Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
The Cooper Companies04602.60

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. The Cooper Companies has a consensus target price of $384.25, suggesting a potential downside of 0.47%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than The Cooper Companies.

Summary

The Cooper Companies beats Cerus on 9 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
DENTSPLY SIRONA-1.40%7.13%4.13%

Valuation & Earnings

This table compares Cerus and DENTSPLY SIRONA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
DENTSPLY SIRONA$4.03 billion3.49$262.90 million$2.4526.20

DENTSPLY SIRONA has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and DENTSPLY SIRONA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
DENTSPLY SIRONA15702.46

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. DENTSPLY SIRONA has a consensus price target of $55.3333, suggesting a potential downside of 13.81%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than DENTSPLY SIRONA.

Summary

DENTSPLY SIRONA beats Cerus on 8 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
Haemonetics11.76%22.85%10.40%

Valuation & Earnings

This table compares Cerus and Haemonetics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
Haemonetics$988.48 million6.02$76.53 million$3.3135.37

Haemonetics has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 1.6% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and Haemonetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
Haemonetics00403.00

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.70%. Given Cerus' higher possible upside, research analysts plainly believe Cerus is more favorable than Haemonetics.

Summary

Haemonetics beats Cerus on 9 of the 13 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
STAAR Surgical5.73%8.99%7.12%

Valuation & Earnings

This table compares Cerus and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
STAAR Surgical$150.18 million35.95$14.05 million$0.46252.07

STAAR Surgical has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and STAAR Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
STAAR Surgical03302.50

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 40.92%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than STAAR Surgical.

Summary

STAAR Surgical beats Cerus on 9 of the 13 factors compared between the two stocks.


Cerus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$592.56+2.8%$46.89 billion$2.41 billion26.96Analyst Downgrade
Gap Up
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$296.52+1.6%$21.90 billion$1.84 billion78.24
The Cooper Companies logo
COO
The Cooper Companies
1.9$386.05+1.3%$18.97 billion$2.43 billion80.26
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$64.20+0.1%$14.06 billion$4.03 billion-279.13
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55Gap Up
STAAR Surgical logo
STAA
STAAR Surgical
1.4$115.95+0.8%$5.40 billion$150.18 million610.30
Quidel logo
QDEL
Quidel
2.4$123.20+4.2%$5.21 billion$534.89 million14.46Gap Down
Neogen logo
NEOG
Neogen
1.2$92.55+2.0%$4.95 billion$418.17 million81.18
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$25.04+2.8%$1.08 billion$253.67 million23.19Analyst Downgrade
Gap Down
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54+1.0%$319.17 million$46.90 million27.62News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.